Ranbaxy: Leveraging on marketing setup - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy: Leveraging on marketing setup

Feb 26, 2002

Ranbaxy has started leveraging on its direct marketing presence in 25 countries across the globe. Yesterday, the company announced entering into an agreement with Penwest, U.S granting Ranbaxy, exclusive marketing rights to market Nifedipine XL, a cardiovascular drug. Ranbaxy would be marketing this drug on behalf of Penwest, USA in key Asian markets such as China, Malaysia, Singapore, Thailand and Sri Lanka. Cumulatively, all these regions have a market close to US$ 50 m for this drug. Though the ultimate revenue occurring to the company at this point of time may be small, it opens new vistas, as it would provide more such opportunities to leverage its marketing set up. Further, it will improve product offerings of the company in its key focus markets besides the US. An improving product basket would improve the bargaining power of the company. UK, Germany, Brazil and China are the other core markets identified by the company.

The speed at which Ranbaxy is cracking export markets is encouraging. The US subsidiaries of the company achieved sales in excess of US$ 113 m. It may be recalled that the company recently got approval for Cefuroxime Axetil in the US markets with expected sales revenues of around US$ 60m. Further, with aggressive product launches, Ranbaxy’s US subsidiaries are likely to cross revenues of US$ 200m in the current financial year.

Considering that most of the identified markets are logging healthy growth rates, the company should continue to log 16-18% CAGR growth over 2005 in exports. The company seems to be ahead of its target in achieving global sales in excess of US$ 1 bn by 2005.

Equitymaster requests your view! Post a comment on "Ranbaxy: Leveraging on marketing setup ". Click here!

  

More Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS